Tandem Diabetes Care, Inc.
TNDMTandem Diabetes Care, Inc. is a medical device company that develops and commercializes products for the management of insulin-dependent diabetes. Founded in 2008 and headquartered in California, the company is known for its innovative insulin pump systems, including the t:slim X2 insulin pump, designed to improve diabetes treatment through advanced technology and user-friendly features. Tandem aims to empower people with diabetes to achieve better health outcomes through integrated and automated insulin delivery solutions.
Company News
Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) following allegations that the company disclosed materially misleading business information. On August 7, 2025, Tandem announced a voluntary recall of its t:slim X2 insulin pumps due to a potential speaker issue that ...
The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the announcement date. Th...
Rosen Law Firm is encouraging investors in Skye Bioscience, SLM Corporation (Sallie Mae), and Tandem Diabetes Care to join securities class action lawsuits. The firm alleges that Skye Bioscience made materially false statements regarding the effectiveness and prospects of its drug nimacimab. Investors who purchased securities during specified cla...
The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care, Inc. following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the announcement. The fir...
The Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care (TNDM) following the company's August 7, 2025 announcement of a voluntary medical device correction for select t:slim X2 insulin pumps due to a speaker-related issue that could discontinue insulin delivery. The stock fell 19.9% on the announcement date. T...
